Added to YB: 2026-06-05
Pitch date: 2026-06-04
RXRX [neutral]
Recursion Pharmaceuticals, Inc.
Author Info
Company Info
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Market Cap
$1.8B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.63
P/E
-2.97
EV/Sales
18.97
Sector
Biotechnology
Category
growth
Recursion Pharmaceuticals: The Drug Factory That Designs Itself
RXRX (overview): AI drug-discovery 'Recursion OS' makes 90% fewer molecules (330 vs 2,500-5,000) at 2x speed (17 vs 40+ mo), stable across quarters. $500M+ cash from Sanofi/Roche/Genentech validates platform. Lead RBM39 degrader dosed in 16 pts, no DLTs. Opex -1/3 YoY, runway to 2028. New operator CEO Khan, 97% equity pay. 7 programs, readouts in 12-18 mo.
Read full article (12 min)